[OFER-TRABEC] NAC: postdoctoral INCOMED

------------------------
(c)OFER-TRABEC es un servicio ofrecido por RedIRIS (Red española para la investigación)
(Permitida la reproducción siempre que se cite la fuente de este Servicio).
*************************
Bolsas de empleo:
http://www.biocat.cat/es/bolsa-de-empleo
------------------------

---Procedencia:
Institución:VHIR
Contacto correo-e:juan.recio@vhir.org
---
Vall d'Hebron Institut de Recerca Vall d'Hebron Institute of Research (VHIR) launches the INCOMED programme, (co-funded by the FP7 Marie Skodowska-Curie COFUND program under Grant Agreement nº 267128), which aims to attract international highly talented scientists in all areas of biomedicine and clinical medicine.

Vall d'Hebron Research Institute (VHIR) is a public sector institution, located in Barcelona (Spain) that promotes and develops innovative biomedical research at the University Hospital Vall d'Hebron. VHIR is oriented towards finding solutions to the health problems of the citizens and has the will to contribute to the scientific, educational, social and economic development within its area of competence.

Benefits
Fellows taking part in the INCOMED programme will benefit from an advanced scientific training programme that includes individual research training, scientific and technology courses, and scientific and financial management of the research project. They will also benefit from career development activities that will include the membership in the VHIR postdoctoral committee, presentation of results at VHIR and international scientific conferences, and participation in laboratory and journal clubs.

Labour conditions:

- Full time position (40h / week).
- Gross annual salary: 34,000€
+ 8,400€ fixed amount designated to expenses linked to laboratory research
+ 6,000€ per year for family relocation

Description
Animal Models and Cancer- Melanoma Group, focus on the molecular basis of melanoma development, progression. By merging the state of the art technology with classical biochemical approaches, genetics and animal models we are committed to contribute to the understanding of malignant melanoma development and progression. More precisely, our goal is the identification of novel molecules and molecular mechanisms involved in this aggressive disease to increase the options for therapeutic intervention. Our investigations also include the testing of new therapeutical approaches using novel drugs in the mouse melanoma model.

The specific work is part of a big project that study the distinct routes of metastatic dissemination in different melanoma subtypes and the validation of new tumor biomarkers and therapeutic targets. All these studies will require the use of mouse animal models and human samples manipulation


----------------
Información complementaria de la oferta:
• Candidates must have a Ph.D. and must have a strong background in at least one of the following areas: tumor biology, molecular biology, cell biology, genomics, genetics, transcriptional and post-transcriptional gene regulation.
• Proven experience in working with animal models: management of mouse colonies and establishment of primary cultures.
• Candidate must be highly motivated
• Must have at least one paper as a first author.
• Be non-resident undertaking trans-national mobility. The researcher must not have lived, worked or studied in the country of the host organization for more than 12 months in the past three years immediately prior to the call deadline.
• Interested applicants should submit a cover letter, CV, contact information for least 2 references and a Research Accomplishment/Interest Summary.


Applicants should complete and submit the online form available at www.vhir.org before September, 22th 2015 and send their CV, motivation letter and contact information from two references to Juan A. Recio PhD. ( juan.recio@vhir.org.)

*************************************************************************
Para darse de baja OFER-TRABEC pinche y envíe:
mailto:OFER-TRABEC-signoff-request@listserv.rediris.es
*************************************************************************